Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Total Current Liabilities (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Total Current Liabilities data on record, last reported at $5.7 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 1.59% year-over-year to $5.7 million; the TTM value through Sep 2025 reached $5.7 million, up 1.59%, while the annual FY2024 figure was $5.4 million, 21.36% down from the prior year.
  • Total Current Liabilities reached $5.7 million in Q3 2025 per MBRX's latest filing, down from $7.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $7.9 million in Q2 2025 and bottomed at $3.4 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $5.4 million, with a median of $5.4 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: surged 74.9% in 2022, then plummeted 38.89% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $3.6 million in 2021, then skyrocketed by 33.05% to $4.8 million in 2022, then skyrocketed by 41.42% to $6.8 million in 2023, then dropped by 21.36% to $5.4 million in 2024, then increased by 6.03% to $5.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $5.7 million in Q3 2025, $7.9 million in Q2 2025, and $6.9 million in Q1 2025.